Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

BACKGROUND: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth Factor Receptor (EGFR) is well validated as a primary contributor of glioma initiation and progression. Nimotuzumab is a humanized monoclonal antibody that recognizes the EGFR extracellular domain and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomón, Maria Teresa, Selva, Julio César, Figueredo, Javier, Vaquer, José, Toledo, Carolina, Quintanal, Nelson, Salva, Silvia, Domíngez, Rafael, Alert, José, Marinello, Jorge Juan, Catalá, Mauricio, Griego, Martha González, Martell, Juan Antonio, Luaces, Patricia Lorenzo, Ballesteros, Javier, de-Castro, Niurys, Bach, Ferdinand, Crombet, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691625/
https://www.ncbi.nlm.nih.gov/pubmed/23782513
http://dx.doi.org/10.1186/1471-2407-13-299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691625/
https://www.ncbi.nlm.nih.gov/pubmed/23782513
http://dx.doi.org/10.1186/1471-2407-13-299

Ejemplares similares